Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 30 - 15

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,651 result(s) found for: 30 - 15. Displaying page 522 of 583.
    «« First « Previous 518  519  520  521  522  523  524  525  526  Next» Last»»
    EudraCT Number: 2014-000275-14 Sponsor Protocol Number: GB29260 Start Date*: 2014-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhal...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001690-25 Sponsor Protocol Number: CT-P17-3.1 Start Date*: 2018-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active R...
    Medical condition: Moderate to Severe Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003486-29 Sponsor Protocol Number: APL-B-022-15 Start Date*: 2016-07-29
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide .
    Medical condition: Multiple Myeloma Double Refractory.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000354-22 Sponsor Protocol Number: A3841029 Start Date*: 2004-12-06
    Sponsor Name:Pfizer Healthcare Ireland
    Full Title: An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)
    Medical condition: Concurrent hypertension (ICD code 80011/MedDRA: coded under preferred term "vascular system order", code 10020772) and dyslipidaemia (ICD code 89212/MedDRA: coded under preferred term "metabolism a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) AT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001258-26 Sponsor Protocol Number: CVAH631B2406 E1 Start Date*: 2006-03-14
    Sponsor Name:Novartis Faarmacéutica S.A
    Full Title: Extensión de 8 semanas de duración del estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, de control activo, de 14 semanas de duración para evaluar la efectividad de la estrateg...
    Medical condition: Essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) GB (Completed) IE (Completed) IT (Completed) DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-003938-18 Sponsor Protocol Number: BY217/M2-125 Start Date*: 2006-01-11
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD. A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000170-20 Sponsor Protocol Number: IM119-015 Start Date*: 2008-06-03
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequa...
    Medical condition: subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005037-30 Sponsor Protocol Number: IC43-201 Start Date*: 2008-11-20
    Sponsor Name:Intercell AG
    Full Title: A PHASE 2 PILOT STUDY ASSESSING IMMUNOGENICITY AND SAFETY OF IC43 IN INTENSIVE CARE PATIENTS
    Medical condition: Nosocomial Pseudomonas aeruginosa infections in mechanically ventilated ICU patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061471 Pseudomonas infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000445-39 Sponsor Protocol Number: BET116183 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic ...
    Medical condition: Patients with relapsed and/or refractory haematological malignancies (lymphoma, leukemia, or multiple myeloma)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006309-96 Sponsor Protocol Number: 0881A6-3326 Start Date*: 2007-06-08
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjecto...
    Medical condition: PSORIASIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) BE (Completed) FI (Completed) ES (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004519-35 Sponsor Protocol Number: PANC2002 Start Date*: 2015-01-09
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreat...
    Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002328-14 Sponsor Protocol Number: OC3-DB-01 Start Date*: 2008-01-10
    Sponsor Name:OxThera Inc.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary H...
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003459-64 Sponsor Protocol Number: AFX01_202 Start Date*: 2009-03-18
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and...
    Medical condition: Anaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058116 Nephrogenic anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019690-15 Sponsor Protocol Number: GLP114179 Start Date*: 2010-07-27
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: Estudio multicéntrico, aleatorizado, abierto y de grupos paralelos para determinar la eficacia y la seguridad de albiglutida en comparación con liraglutida en pacientes con diabetes mellitus de tip...
    Medical condition: Diabetes mellitus de tipo 2. Type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004222-17 Sponsor Protocol Number: H6D-MC-LVHX Start Date*: 2009-01-30
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhib...
    Medical condition: Erectile dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061461 Erectile dysfunction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023483-41 Sponsor Protocol Number: I10E-0718 Start Date*: 2011-03-01
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)
    Medical condition: a primary immunodeficiency as defined by the ESID and validated by a reference centre : • X-linked agammaglobulinemia (XLA) • Common variable immunodeficiency (CVID)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10010112 Common variable immunodeficiency LLT
    14.1 100000004870 10036700 Primary immunodeficiency syndromes HLT
    14.1 100000004870 10001471 Agammaglobulinemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2013-003452-21 Sponsor Protocol Number: BRF117277 Start Date*: 2014-01-27
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain.
    Medical condition: Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003669-14 Sponsor Protocol Number: ISRCTN15088122 Start Date*: 2012-12-03
    Sponsor Name:London School Of Hygiene and Tropical Medicine
    Full Title: Tranexamic Acid for the treatment of significant traumatic brain injury: an international, randomised, double blind, placebo controlled trial.
    Medical condition: Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10060690 Traumatic brain injury LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IT (Completed) IE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2006-005523-42 Sponsor Protocol Number: 905-EC-005 Start Date*: 2007-09-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride ...
    Medical condition: Neurogenic detrusor overactivity.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) GB (Completed) HU (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002576-18 Sponsor Protocol Number: A4061027 Start Date*: 2006-11-24
    Sponsor Name:Pfizer Ltd.
    Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT
    Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055107 Thyroid cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 518  519  520  521  522  523  524  525  526  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 23:56:55 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA